All inhaled corticosteroids (ICSs) exert their pharmacologic effects through the same mechanism. This review examines pharmacokinetic profiles of ICSs to explain the variations in efficacy and adverse effects seen with these agents and identify ideal properties for an optimal ICS. For optimum efficacy and safety, the ideal ICS would have high pulmonary bioavailability with pulmonary activation for targeted delivery, negligible oral bioavailability, high plasma protein binding, rapid systemic clearance, and sustained pulmonary residence to permit once-daily dosing.
Document Type: Research Article
Publication date: September 1, 2005
More about this publication?
Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.